Building India Capability Without Building an Entity

Executive Summary

India has become the world’s largest hub for life sciences services, with over 60% of global clinical trials now involving Indian sites and a rapidly expanding biometrics, data management, and regulatory talent pool. For CROs and pharmaceutical sponsors, the question is no longer whether to establish India-based capability but how to do so with speed, compliance, and governance.

Three models exist for building global capability: establishing a legal entity, using Employer of Record (EOR) arrangements, or engaging a structured capability deployment partner. Each model involves distinct trade-offs in cost, timeline, control, compliance, and scalability.

This whitepaper provides an honest assessment of all three models and introduces the structured deployment approach, a model that combines the compliance rigor of entity-based operations with the speed and flexibility of EOR, governed by healthcare-grade discipline built over two decades of regulated industry delivery.

1. India as a Strategic Capability Hub

The scale of India’s life sciences talent ecosystem is significant. According to the India Brand Equity Foundation (IBEF), India’s pharmaceutical industry is the third largest in the world by volume and is projected to reach $130 billion by 2030. The country produces over 750,000 STEM graduates annually, with a growing proportion specializing in biostatistics, clinical data management, pharmacovigilance, and regulatory affairs.

1.1 Beyond Cost Arbitrage

The first generation of India offshoring was driven primarily by cost reduction. The current wave is different. CROs and sponsors are building India capability for three strategic reasons that extend beyond labour cost:

• Talent density. India has the largest concentrated pool of biometrics, SAS programming, clinical data management, and medical writing professionals outside of the United States and Europe. The National Association of Software and Service Companies (NASSCOM) estimates that India’s technology services workforce exceeds 5.4 million, with life sciences services growing at 14% annually.

• Regulatory maturity. India’s Central Drugs Standard Control Organisation (CDSCO) has progressively aligned with ICH-GCP guidelines, and India’s inclusion in the PIC/S (Pharmaceutical Inspection Co-operation Scheme) reflects growing international confidence in the country’s regulatory framework.

• Timezone coverage. India’s timezone (IST, UTC+5:30) enables nearly continuous operations when combined with US and European teams. For clinical trial data management and safety reporting, this coverage reduces cycle times and accelerates submissions.

1.2 The Urgency for CROs

For mid-size and large CROs, India capability is becoming a competitive necessity. Clients increasingly expect India-based delivery as part of the baseline proposal, not as an optional cost reduction. CROs without established India operations are finding themselves at a structural disadvantage in bids against competitors who have already made the investment.

The challenge is that building India capability through a legal entity takes 6–12 months and requires significant upfront capital, legal complexity, and ongoing administrative overhead. For many CROs, particularly those in growth phases or undergoing organizational transformation, this timeline is incompatible with their competitive needs.

2. Three Models for India Capability

Each model for building India capability involves distinct trade-offs. Understanding these trade-offs clearly is essential for making the right choice.

2.1 Entity Setup

Establishing a legal entity in India (typically a private limited company or LLP) provides maximum control over operations, hiring, intellectual property, and data. It is the right choice for organizations planning sustained, large-scale operations with 100+ employees and a multi-year commitment.

However, the entity setup model carries significant constraints. Incorporation requires registration with the Registrar of Companies, obtaining a Permanent Account Number (PAN), Tax Deduction Account Number (TAN), and Goods and Services Tax (GST) registration. Labor law compliance includes the Employees’ Provident Fund, Employees’ State Insurance, gratuity provisions, and state-specific Shops and Establishments Act registration. The timeline from decision to first operational hire is typically 6–12 months.

2.2 Employer of Record (EOR)

EOR arrangements allow a CRO to hire employees in India without establishing a legal entity. The EOR provider serves as the legal employer, managing payroll, tax withholding, benefits administration, and labor law compliance. The CRO retains functional management of the employee.

EOR is well-suited for small teams (5–20 people) or pilot operations where the CRO wants to test India capability before committing to entity establishment. The limitation is that EOR provides a hiring mechanism, not a capability deployment model. The CRO must still source, vet, and manage the individuals, and there is no inherent governance framework governing how the team operates.

2.3 Structured Capability Deployment

The structured deployment model combines EOR-based employment with a comprehensive capability and governance layer. The deployment partner (SIRO, in this case) manages not just the employment logistics but the entire capability stack: team composition, skill assessment, governance framework, operating rhythms, quality assurance, and delivery management.

This model is designed for CROs and sponsors who need India capability operational in weeks, not months, and who cannot afford to compromise on governance and compliance in a regulated environment.

3. Governance in Regulated Deployment

3.1 The Governance Gap in Standard EOR

Standard EOR providers excel at employment compliance, payroll, taxes, labor law. They do not typically provide delivery governance. This creates a gap for CROs deploying teams in regulated workflows:

• No SOP framework governing day-to-day operations
• No quality assurance protocols specific to clinical or regulatory work
• No audit-readiness or documentation standards
• No training validation or competency assessment framework
• No escalation paths or incident management protocols

For non-regulated work, this gap may be manageable. For clinical data management, biostatistics output, or medical writing, it introduces compliance risk that can affect regulatory submissions, audit outcomes, and ultimately patient safety.

3.2 Healthcare-Grade Governance in Deployment

SIRO’s governance framework was built in regulated environments where non-compliance has direct consequences for patient safety and regulatory approval. This framework includes:

• SOP-driven operations. Every process, from onboarding to deliverable review to escalation, is governed by standard operating procedures that are versioned, trained, and auditable.
• Competency validation. Team members are assessed against role-specific competency frameworks before deployment. Training gaps are closed before, not after, the team begins delivery.
• Quality assurance. All deliverables pass through quality checkpoints with defined acceptance criteria, review protocols, and documentation requirements.
• Audit readiness. Documentation, training records, and process artifacts are maintained at a level that supports regulatory audit at any time.
• Data security and privacy. Data handling protocols comply with GDPR, HIPAA, and country-specific data protection requirements, with encryption, access controls, and audit trails built into the operating environment.

4. The SIRO Deployment Model

SIRO’s structured deployment model for India capability operates across four phases:

Phase 1: Capability Design (Week 1)

Working with the CRO or sponsor, SIRO maps the capability requirement: roles, skills, seniority levels, domain expertise, regulatory requirements, and delivery timelines. The output is a team blueprint, a detailed specification of the team as a functioning unit, not a list of job descriptions.

Phase 2: Team Assembly (Weeks 1–2)

SIRO sources and assesses candidates against the team blueprint, including competency validation, domain expertise assessment, and governance readiness evaluation. Team members are selected for both individual capability and team complementarity.

Phase 3: Governance Activation (Week 2–3)

Before the team begins delivery, the governance framework is activated: SOPs are deployed, training is completed and validated, quality protocols are established, and reporting cadences are set. The team is delivery-ready before they write their first line of code or their first clinical narrative.

Deployment and Continuous Governance (Week 3+)

The team begins delivery within the CRO’s operating framework, with SIRO maintaining governance oversight. Regular quality reviews, performance assessments, and governance audits ensure sustained compliance and delivery quality. Scaling is managed through the same structured process, additional capacity is deployed as designed teams, not ad-hoc additions.

Case Pattern: A mid-size CRO needed a 7-person biometrics team (2 biostatisticians, 3 SAS programmers, 1 clinical data manager, 1 medical writer) deployed in India within 4 weeks. No entity existed. SIRO deployed the full team in 18 days, with governance framework active before the first deliverable. The team achieved production-level quality within the first review cycle.

5. Decision Framework for CROs and Sponsors

Choosing the right India deployment model depends on five factors:

6. Conclusion

India capability is no longer optional for CROs and pharmaceutical sponsors competing in global clinical development. The question is not whether to build India capability but how to build it without the overhead, risk, and timeline of entity establishment.

The structured deployment model, combining EOR-based employment with healthcare-grade governance and pre-composed team design, closes the gap between the speed of EOR and the control of an entity. For regulated environments where compliance is non-negotiable, this model provides the governance depth that standard EOR cannot deliver.

SIRO Functional Services has spent over two decades building and operating in regulated environments. Our deployment model is not a theoretical framework, it is the operating model we use every day to deploy structured teams across biometrics, clinical data, medical writing, and regulatory workflows. We bring this same discipline to every India capability engagement.

References

1. India Brand Equity Foundation (IBEF). “Indian Pharmaceutical Industry Report.” IBEF, 2025.
2. NASSCOM. “Technology Sector in India: Strategic Review 2025.” National Association of Software and Service Companies, 2025.
3. World Economic Forum. “The Future of Jobs Report 2025.” WEF, Geneva, 2025.
4. Central Drugs Standard Control Organisation (CDSCO). “Guidelines for Clinical Trials.” Ministry of Health and Family Welfare, Government of India.
5. ICH. “ICH E6(R2) Guideline for Good Clinical Practice.” International Council for Harmonisation, 2016.
6. Deloitte. “2024 Global Life Sciences Outlook: Accelerating Transformation.” Deloitte Insights, 2024.
7. McKinsey & Company. “India Pharma 2030: From Generics to Global Leader.” McKinsey India, 2024.
8. EY. “Employer of Record: Navigating Global Workforce Compliance.” Ernst & Young LLP, 2024.
9. PIC/S. “Pharmaceutical Inspection Co-operation Scheme: India Accession.” PIC/S Secretariat, 2023.
10. Gartner. “Top Trends in Life Sciences for 2025.” Gartner Research, 2025.